Intra-Cellular Therapies gets FDA nod for Caplyta

Intra-Cellular Therapies has received the Food and Drug Administration’s blessing for Caplyta (lumateperone) for the treatment of schizophrenia in adults.

“We believe Caplyta provides healthcare providers a new, safe and effective treatment option to help the millions of adult patients with schizophrenia,” said Sharon Mates, chairman and CEO of Intra-Cellular Therapies.

Mates added,“This approval represents the culmination of years of scientific research. We are especially grateful to the patients, their caregivers, and the healthcare professionals who have contributed to the development of Caplyta.”

The company expects to initiate the commercial launch of the product in late Q1 of 2020.